Avanza Fonder AB Buys New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Avanza Fonder AB bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 85,860 shares of the company's stock, valued at approximately $580,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals during the third quarter worth $25,000. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. GAMMA Investing LLC boosted its stake in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after purchasing an additional 4,091 shares in the last quarter. Finally, Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $8.75.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded up $0.13 during mid-day trading on Monday, reaching $6.53. The company's stock had a trading volume of 9,880,924 shares, compared to its average volume of 13,858,955. The firm's fifty day moving average price is $6.90 and its two-hundred day moving average price is $6.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74. The company has a market capitalization of $2.55 billion, a P/E ratio of -4.27 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity

In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the completion of the sale, the director now owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,894 shares of company stock worth $317,139. 15.75% of the stock is owned by company insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.